Libmeldy (Atidarsagene Autotemcel)

What Is Libmeldy and What Is It Used For?

Libmeldy (atidarsagene autotemcel) is an advanced therapy medicinal product (ATMP) classified as a haematopoietic stem and progenitor cell (HSPC) gene therapy. It represents a groundbreaking approach to treating metachromatic leukodystrophy (MLD), a rare autosomal recessive lysosomal storage disorder that affects approximately 1 in 40,000 to 1 in 160,000 live births worldwide. MLD is caused by mutations in the ARSA gene, which encodes the enzyme arylsulfatase A. Without functional ARSA, a fatty substance called sulfatide accumulates in cells throughout the body, particularly in the nervous system, progressively destroying the myelin sheath that insulates nerve fibres.

The destruction of myelin leads to devastating and irreversible neurological decline. Children with MLD progressively lose the ability to walk, speak, see, hear, and eventually swallow and breathe. The late infantile form, which is the most common and severe, typically presents between ages 6 months and 2 years, with death often occurring within 5 years of symptom onset. The early juvenile form presents between ages 3 and 7 years, with a somewhat slower but equally relentless progression.

Libmeldy works by a process known as ex vivo gene therapy. The patient's own CD34+ haematopoietic stem and progenitor cells are collected via bone marrow harvest. These cells are then genetically modified in a specialised laboratory using a lentiviral vector — a harmless, modified virus — that inserts a functional copy of the human ARSA gene into the cells' DNA. After the patient undergoes myeloablative conditioning with busulfan (a type of intensive chemotherapy that clears the bone marrow), the genetically modified cells are infused back into the patient intravenously.

Once infused, the modified cells engraft in the bone marrow and begin producing functional ARSA enzyme. Crucially, a subset of these cells differentiates into microglia (immune cells of the brain) and macrophages, which migrate across the blood-brain barrier into the central nervous system. There, they secrete ARSA enzyme, which is taken up by neighbouring cells through a process called cross-correction. This mechanism allows the therapy to address sulfatide accumulation in both the peripheral and central nervous systems.

Approved Indications

Libmeldy is specifically indicated for children with MLD characterised by biallelic mutations in the ARSA gene, in the following populations:

• Late infantile form: Children who are pre-symptomatic (have not yet developed clinical manifestations of MLD)
• Early juvenile form: Children who are either pre-symptomatic, or who are in the early symptomatic stage and still have the ability to walk independently, with no onset of cognitive decline

What Should You Know Before Taking Libmeldy?

Before a child can receive Libmeldy, extensive medical evaluation is required to ensure they are eligible and that the potential benefits outweigh the risks. The treatment process is complex and involves several weeks of preparation, including stem cell collection, manufacturing of the gene therapy product, and conditioning chemotherapy. Families must understand the full treatment journey and the long-term monitoring requirements.

Contraindications

Libmeldy must not be given in the following situations:

• Hypersensitivity to the active substance or any of the excipients, including dimethylsulfoxide (DMSO)
• Previous haematopoietic stem cell gene therapy — patients who have previously received any gene therapy involving haematopoietic stem cells are not eligible
• Contraindications to mobilisation agents or myeloablative conditioning — patients who cannot receive busulfan chemotherapy due to medical reasons

Warnings and Precautions

There are several important warnings and precautions associated with Libmeldy treatment:

Specialised treatment centres: Libmeldy must only be administered at qualified treatment centres with documented experience in haematopoietic stem cell transplantation (HSCT). The healthcare team must have specific training in the administration of this gene therapy product.

Autologous use only: Libmeldy is manufactured from the patient's own cells and must only be given to the patient for whom it was made. Strict identity verification procedures must be followed before administration to prevent mix-ups.

Myeloablative conditioning risks: Before infusion, the patient must undergo myeloablative conditioning with busulfan, which carries significant risks including prolonged and severe cytopenia (dangerously low blood cell counts), febrile neutropenia, infections, and veno-occlusive liver disease. Patients require intensive supportive care during this period.

Engraftment failure: There is a risk that the modified cells may not successfully engraft in the bone marrow. Engraftment failure is defined as an absolute neutrophil count below 500 cells per microlitre with hypocellular bone marrow by day 60 post-infusion. A rescue bone marrow infusion must be available as a safety measure.

Insertional oncogenesis: As with any gene therapy using a viral vector, there is a theoretical risk that the lentiviral vector could insert into the DNA near a gene that promotes cancer development, potentially leading to leukaemia or lymphoma. While no cases of insertional oncogenesis have been reported in clinical trials with Libmeldy, long-term monitoring for at least 15 years after treatment is required.

False positive HIV tests: Because the lentiviral vector used in Libmeldy is derived from HIV, patients may test positive on HIV nucleic acid tests (PCR) after treatment. This is a false positive result. Healthcare providers should be informed about the patient's treatment history before any HIV testing.

Anti-ARSA antibodies: Approximately 14% of patients in clinical trials developed antibodies against the ARSA enzyme. In most cases, these antibodies were at low levels and resolved spontaneously or with rituximab treatment. Anti-ARSA antibody levels are monitored at regular intervals for up to 15 years after treatment.

Pregnancy and Breastfeeding

Libmeldy is indicated for use in children, and pregnancy and breastfeeding considerations relate primarily to the myeloablative conditioning agent busulfan rather than to the gene therapy product itself. Busulfan is known to be teratogenic and can cause infertility. Ovarian failure was reported as a common side effect in clinical trials. Families should discuss fertility preservation options with the medical team before treatment begins. The long-term reproductive effects of the gene therapy itself are not fully known and are subject to ongoing monitoring.

How Does Libmeldy Interact with Other Drugs?

Because Libmeldy is a single-dose gene therapy rather than a conventional medication taken repeatedly, its drug interactions are primarily related to the treatment process and the myeloablative conditioning phase. However, several important interactions must be managed carefully to ensure the safety and efficacy of the treatment.

The lentiviral vector used to modify the patient's stem cells is derived from HIV, which means that anti-retroviral medications could potentially interfere with the transduction process. Similarly, the myeloablative conditioning with busulfan and the subsequent immune recovery period create windows of vulnerability where certain medications must be avoided.

Major Interactions

Minor Interactions

No formal drug-drug interaction studies have been conducted with Libmeldy because it is administered as a one-time infusion of genetically modified cells. Once the cells have engrafted and the patient has recovered from conditioning, there are no ongoing drug interactions associated with the gene therapy itself. Patients should discuss all current medications with their transplant team before beginning the treatment process to ensure a safe treatment course.

The pre-medication chlorpheniramine (an antihistamine), given 15–30 minutes before infusion at a dose of 0.25 mg/kg (maximum 10 mg intravenously), is specifically recommended to reduce the risk of allergic reactions to the DMSO contained in the product formulation. This is not an interaction per se but rather a standard part of the treatment protocol.

What Is the Correct Dosage of Libmeldy?

Unlike conventional medications with fixed daily doses, Libmeldy is a personalised gene therapy manufactured from the patient's own stem cells. The treatment is given once, and the dose is determined by the number of genetically modified CD34+ cells obtained during the manufacturing process. Each patient's treatment is unique, and the dosage is expressed as the number of CD34+ cells per kilogram of body weight.

Treatment Process and Administration

Dosing Information

Children

Libmeldy is exclusively indicated for use in children. The dose is weight-based (cells per kilogram), ensuring appropriate scaling for paediatric patients of different sizes. All patients treated in clinical trials were children, and the safety and efficacy data are derived entirely from the paediatric population. The treatment approach is the same regardless of the child's age within the indicated population.

Adults and Elderly

Libmeldy is not indicated for adults or elderly patients. The approved indications are limited to children with early-onset forms of MLD (late infantile and early juvenile). Adult-onset MLD is not an approved indication, and there are no clinical data supporting the use of Libmeldy in adult patients.

Missed Dose

The concept of a missed dose does not apply to Libmeldy, as it is a one-time treatment administered in a controlled hospital setting under direct medical supervision. The infusion is carefully planned and scheduled as part of the transplant protocol, and there is no possibility of accidentally missing a dose.

Overdose

No cases of overdose have been reported with Libmeldy. The dose is determined by the manufacturing process for each individual patient, and administration occurs under strict medical supervision. In the unlikely event of an adverse reaction during infusion, the infusion can be slowed or stopped, and standard supportive care measures would be implemented.

What Are the Side Effects of Libmeldy?

Understanding the side effect profile of Libmeldy requires distinguishing between effects caused by the gene therapy itself and those caused by the myeloablative conditioning with busulfan that precedes it. The conditioning phase is essential for the treatment to work, as it clears the bone marrow to allow the genetically modified cells to engraft, but it carries the same risks as any high-dose chemotherapy regimen used in stem cell transplantation.

In clinical trials, 29 patients with early-onset MLD were evaluated for safety. The following side effects were observed, categorised by frequency according to international medical convention. Most adverse events were consistent with those expected from myeloablative conditioning and were manageable with standard supportive care.

Side Effects Directly Related to Libmeldy

Side Effects Related to Myeloablative Conditioning (Busulfan)

Patients typically experience the most severe side effects during the 4–6 weeks following conditioning and infusion, when blood cell counts are at their lowest (the nadir period). Neutrophil recovery generally occurs within 4–5 weeks post-infusion, although approximately 11% of patients experienced delayed platelet engraftment beyond 60 days. All patients in clinical trials eventually achieved haematological recovery.

How Effective Is Libmeldy Based on Clinical Evidence?

The clinical evidence for Libmeldy comes from an integrated analysis of 29 children with early-onset MLD: 20 from the pivotal registrational study (median follow-up of 4.0 years) and 9 from expanded access programmes (median follow-up of 1.5 years). Results were compared against a well-characterised natural history cohort of untreated MLD patients.

Motor Function Outcomes

Motor function was assessed using the Gross Motor Function Measure (GMFM) total score, a validated tool for measuring motor abilities in children with neurological conditions. The results were striking:

• Pre-symptomatic late infantile patients: Mean GMFM score of 72.5 at year 2, compared to 7.4 in untreated patients (p<0.001). By year 3, treated patients showed 79.8% improvement over baseline.
• Pre-symptomatic early juvenile patients: Mean GMFM score of 76.5 at year 2, compared to 36.3 in untreated patients (p=0.008). At year 3, a 74.9% improvement was observed.
• Early symptomatic early juvenile patients: More modest improvements of 28.7% at year 2 and 43.9% at year 3, underscoring the importance of early treatment.

Survival

Survival data demonstrated a dramatic benefit. Among pre-symptomatic late infantile patients, all 16 treated patients (100%) were alive at 6 years, compared to only 58–63% of patients in the natural history cohort over the same period. This represents a substantial and clinically meaningful survival advantage for a disease that is uniformly fatal without treatment.

Cognitive Outcomes

Cognitive preservation was one of the most important findings. Among late infantile patients, 12 of 15 evaluable patients maintained IQ/DQ scores within the normal range. All treated patients remained above the threshold for severe cognitive impairment, while all untreated patients in the comparison group showed severe cognitive decline. In the broader FDA evaluation of 37 children, 85% achieved normal language development and IQ scores.

ARSA Enzyme Activity

The fundamental goal of the therapy — restoring ARSA enzyme production — was convincingly achieved. Pre-symptomatic patients showed a 20-fold increase in ARSA enzyme activity at year 2 compared to baseline (p<0.001). Early symptomatic patients showed a 4.2-fold increase (p=0.004). ARSA activity in cerebrospinal fluid (CSF), reflecting enzyme production in the central nervous system, was undetectable at baseline but reached the normal reference range by approximately 1 year post-treatment.

Engraftment Durability

The genetically modified cells demonstrated durable multilineage engraftment from 1 month post-infusion in all evaluable patients. At year 1, approximately 54.8% of bone marrow-derived colonies harboured the lentiviral vector genome, and this remained stable at 45.0% at year 5, indicating long-term persistence of the genetic correction.

How Should You Store Libmeldy?

Libmeldy is a living cell therapy product that requires very specific storage and handling conditions to maintain cell viability and therapeutic effectiveness. The product is manufactured individually for each patient and is supplied as a cryopreserved dispersion in infusion bags contained within an overwrap bag inside a metal cassette.

Storage temperature: The product must be stored in the vapour phase of liquid nitrogen at a temperature below −130°C. This ultra-cold storage is essential to preserve the viability of the genetically modified stem cells. The treatment centre must have appropriate cryogenic storage facilities.

Transport: Libmeldy is shipped from the manufacturing facility to the treatment centre in a validated cryoshipper designed to maintain the required ultra-low temperatures during transit. The product should not be removed from the cryoshipper until the patient is ready for treatment.

Thawing: The product must be thawed at the bedside immediately before administration. Once thawing begins, the infusion must be completed within 2 hours. The product must never be refrozen after thawing.

Shelf life: The shelf life is patient-specific and depends on the manufacturing batch. Detailed lot information, including expiry date, is provided on the accompanying documentation and the cryoshipper lid.

Traceability: Owing to the nature of this autologous gene therapy product, records linking the patient to the product must be maintained for a minimum of 30 years after the product's expiry date. This is a regulatory requirement to enable long-term safety monitoring and traceability.

What Does Libmeldy Contain?

Libmeldy is a unique pharmaceutical product in that its primary active component consists of the patient's own living cells. Understanding its composition is important for healthcare providers who manage the infusion and monitor for potential reactions.

Active Substance

The active substance is atidarsagene autotemcel: autologous CD34+ haematopoietic stem and progenitor cells (HSPCs) that have been genetically modified ex vivo using a third-generation, self-inactivating, VSV-G pseudotyped lentiviral vector to express the human arylsulfatase A (ARSA) gene. The cell concentration in the final product is 2–10 × 10⁶ cells per millilitre.

Excipients

The cryopreservation solution contains the following excipients of note:

• Dimethylsulfoxide (DMSO): Present at a concentration of 55 mg/mL. DMSO is a cryoprotectant that helps preserve cell viability during freezing and thawing. It can cause allergic reactions in some patients, which is why pre-medication with chlorpheniramine is required before infusion.
• Sodium: Present at 3.5 mg/mL. The sodium content should be taken into account for patients on sodium-restricted diets, although the total amount administered during infusion is generally small.

The product does not contain any preservatives, dyes, or inactive pharmaceutical ingredients beyond the cryopreservation solution. Because it is a living cell product, it cannot be sterilised by conventional methods such as filtration or irradiation.

Lentiviral Vector

The lentiviral vector used for gene transfer is a replication-incompetent, self-inactivating vector pseudotyped with the vesicular stomatitis virus G protein (VSV-G). While derived from HIV-1, the vector has been extensively modified to remove all viral genes capable of replication. It carries only the therapeutic ARSA gene along with regulatory elements needed for gene expression. After transduction of the stem cells, the vector integrates into the cellular DNA, allowing stable, long-term expression of functional ARSA enzyme.

What Is the Regulatory Approval Status of Libmeldy?

Libmeldy has undergone rigorous regulatory evaluation by multiple medicines authorities worldwide, reflecting both the innovative nature of the therapy and the high standards applied to gene therapy products.

The FDA granted Libmeldy (marketed as Lenmeldy in the US) several special designations reflecting the unmet medical need: Priority Review, Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations. NHS England approved reimbursement in February 2022, making it available to eligible UK patients.

Libmeldy is among the most expensive therapies in the world, with a US list price of approximately $4.25 million for the single one-time treatment. In Europe, pricing varies by country and is typically negotiated through managed entry agreements with national health authorities. The high cost reflects the personalised manufacturing process, the rarity of the condition, and the one-time curative intent of the therapy.

The marketing authorisation holder for the EU is Orchard Therapeutics (Netherlands) BV, which became a wholly-owned subsidiary of Kyowa Kirin following the completed acquisition of Orchard Therapeutics in January 2024 for $477 million. The therapy was originally developed in partnership with the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.